Functional analysis of eicosanoids from white blood cells in sepsis and SIRS

Journal of Physiology and Pharmacology

Volumn 57, Issue SUPPL. 12, 2006, Pages 25-33

  Baenkler, M ^a   Leykauf, M ^a   John, S ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Eicosanoids; Inflammatory response; Leukotrienes; Prostaglandins; Sepsis; Systemic Inflammatory Response Syndrome (SIRS)

Indexed keywords

ARACHIDONIC ACID; ICOSANOID; LEUKOTRIENE; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN; PROSTAGLANDIN E2;

ADULT; AGED; CENTRIFUGATION; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; LEUKOCYTE; MALE; OUTCOME ASSESSMENT; PROSTAGLANDIN BLOOD LEVEL; SEPSIS; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ADULT; AGED; ARACHIDONIC ACID; CASE-CONTROL STUDIES; DINOPROSTONE; EICOSANOIDS; FEMALE; HUMANS; LEUKOCYTES; LEUKOTRIENES; MALE; PROGNOSIS; SEPSIS; SURVIVORS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 34147163381     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
2. Seeger W, Grimminger F, Walmrath D. Mediatorblockade und Immunmodulation - Konzepte und Praxisreifes. In Sepsis und MODS, K Werdan, HP Schuster, U Müller-Werdan (eds). Berlin, Springer, 2005, pp. 253-263.
3. Levy MM, Fink PF, Ramsay G, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 1992; 20(6): 864-874.
4. Kragsbjerg P, Holmberg H, Vikersfors T. Serum Concentrations of Interleukin-6, Tumour Necrosis Factor-α, and C-Reactive Protein in Patients Undergoing Major Operation. Eur J Surg 1995; 161: 17-22.
5. Bone AE. Sir Isaac Newton, sepsis, SIRS and CARS. Crit Care Med 1996; 24: 1125-1128.
6. De Waal Malefyt R, Abrams J, Bennett B, et al. Interleukin 10 (Il-10) and viral Il-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class II major histocompatibility complex expression. J Exp Med 1991; 174: 915-924.
7. Williams MA, Whington S, Newland AC, et al. Monocyte anergy in septic shock is associated with a predilection to apoptosis and is reversed by granulozyt-macrophage colony-stimulating factor ex vivo. J Infect Dis 1998; 178: 1421-1433.
8. Müller-Werdan U, Schuster HP. Abriss der Pathophysiologie als Grundlage der Therapie. In Sepsis und MODS, K Werdan, HP Schuster, U Müller-Werdan (eds). Berlin, Springer, 2005, pp.34-44.
9. Morlion BJ, Torwesten E, Kuhn KS, Puchstein C, Fürst P. Cysthenyl-leukotriene generation as a biomarker for survival in the critical ill. Crit Care Med 2000; 28: 3655-3658.
10. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13(10): 818-829.
11. Schafer D, Baenkler HW. Functional eicosanoid test and typing (FET) of peripheral blood cells in eicosanoids related diseases. J Physiol Pharmacol 2005; 56 Suppl 5: 103-118.
12. Wolfe RR, Herndon DN, Jahoor F, Miyoshi H, Wolfe M. Effect of severe burn injury on substrate cycling by glucose and fatty acids. N Engl J Med 1987; 317: 403-408.
13. Heyland DK, Novak F, Drover JW, Jain M, Su X, Suchner U. Should immunonutrition become routine in critically ill patients? A systematic review of the evidence. JAMA 2001; 286: 944-953.
14. Bulger EM, Maier RV. Lipid mediators in the pathophysiology of critical illness. Crit Care Med 2000; 28(4): N27-N36.
15. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med 1997; 336: 912-918.
16. Arons MM, Wheeler AP, Bernard GR, et al. Effects of ibuprofen on the physiology and survival hypothermic sepsis. Crit Care Med 1999; 27: 699-707.
17. Sakamoto A, Matsumura J, Mii S, Gotoh Y, Ogawa R. A prostaglandin E2 receptor subtype EP4 agonist attenuates cardiovascular depression in endotoxin shock by inhibiting inflammatory cytokines and nitric oxide production. Shock 2004; 22: 76-81.
18. Cavaillon JM. "Septic plasma": an immunosuppressive milieu. Am J Respir Crit Care Med 2002; 166: 1417-1418.
19. De Waal Malefyt R, Abrams J, Bennett B, et al. Interleukin 10 (Il-10) and viral Il-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class II major histocompatibility complex expression. J Exp Med 1991; 174: 915-924.
20. Tavares-Murta BM, Zaparoli M, Ferreira RB. Failure of neutophil chemotactic function in speptic patients. Crit Care Med 2002 May; 30(5): 1056-1061.
21. Geissmann F, Jung S, Littmann DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003; 19: 71-82.
22. Cavaillon JM, Adrie C, Fitting C, Adib-Conquy M. Reprogramming of circulatory cells in sepsis and SIRS. J Endotoxin Res 2005; 11: 311-320.
23. Fumeaux T, Dufour J, Stern S, Pugin J. Immune monitoring of patients with septic shock by measurement of intraleukocyte cytokines. Intensive Care Med 2004; 30(11): 2028-2037.